the purpose of this investigation was to assess the effect of captopril on both systemic (p.a) and pulmonary arterial pressures (ppa) in patients with high-altitude pulmonary hypertension (haph). seventeen patients (mean age 44±6.8 years) with haph and mild to moderate systemic arterial hypertension were included in the study. all patients underwent right heart catheterization with measurements...

Pulmonary vasoconstriction represents a physiological adaptive mechanism to high altitude. If exaggerated, however, it is associated with important morbidity and mortality. Recent mechanistic studies using short-term acute high altitude exposure have provided insight into the importance of defective vascular endothelial and respiratory epithelial nitric oxide (NO) synthesis, increased endotheli...

Pulmonary arterial hypertension in man at altitude was first demonstrated by Rotta, Canepa. Hurtado. Velasquez & Chavez (1956). One year before Vega (1955) had published the first comprehensive clinical account of high altitude pulmonary oedema. Since the mid-sixties. interest in both pulmonary hypertension and pulmonary oedema at altitude has continued to generate a great deal of clinical and ...

BACKGROUND Pulmonary hypertension is a hallmark of high-altitude pulmonary edema and may contribute to its pathogenesis. When administered by inhalation, nitric oxide, an endothelium-derived relaxing factor, attenuates the pulmonary vasoconstriction produced by short-term hypoxia. METHODS We studied the effects of inhaled nitric oxide on pulmonary-artery pressure and arterial oxygenation in 1...

Pulmonary hypertension had long been suspected in high-altitude natives of the Andes. However, it remained for a team of Peruvian scientists led by Dante Penaloza to provide not only the first clear evidence that humans living at high altitude did indeed have chronic, and occasionally severe, pulmonary hypertension, but more importantly, that this was a consequence of structural changes in the ...

Many pathological conditions, like sleep apnea (SA), preeclampsia, high altitude sickness, and chronic obstructive pulmonary disease, that cause intermittent or chronic hypoxia, are often associated with the development of either systemic or pulmonary hypertension. Mechanisms sensing hypoxia may be important contributors to the development of pulmonary hypertension and to tissue injury and repa...

The unusually muscular pulmonary arteries normally present in cattle and swine residing at low altitude are associated with a rapid development of severe pulmonary hypertension when those animals are moved to high altitude. Because these species lack collateral ventilation, they appear to have an increased dependence on hypoxic vasoconstriction to maintain normal ventilation-perfusion balance, ...

High-altitude pulmonary hypertension (HAPH) is a specific disease affecting populations that live at high elevations. The prevalence of HAPH among those residing at high altitudes needs to be further defined. Whereas reduction in nitric oxide production may be one mechanism for the development of HAPH, the roles of endothelin-1 and prostaglandin I₂ pathways in the pathogenesis of HAPH deserve f...

High-altitude destinations are visited by increasing numbers of children and adolescents. High-altitude hypoxia triggers pulmonary hypertension that in turn may have adverse effects on cardiac function and may induce life-threatening high-altitude pulmonary edema (HAPE), but there are limited data in this young population. We, therefore, assessed in 118 nonacclimatized healthy children and adol...